The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Inhibition of Hypoxia-inducible Factor (HIF) Hydroxylases by Citric Acid Cycle Intermediates
Open accessAbstract
The stability and transcriptional activity of the hypoxia-inducible factors (HIFs) are regulated by two oxygen-dependent events that are catalyzed by three HIF prolyl 4-hydroxylases (HIF-P4Hs) and one HIF asparaginyl hydroxylase (FIH). We have studied possible links between metabolic pathways and HIF hydroxylases by analyzing the abilities of citric acid cycle intermediates to inhibit purified human HIF-P4Hs and FIH. Fumarate and succinate were identified as in vitro inhibitors of all three HIF-P4Hs, fumarate having K(i) values of 50-80 microM and succinate 350-460 microM, whereas neither inhibited FIH. Oxaloacetate was an additional inhibitor of all three HIF-P4Hs with K(i) values of 400-1000 microM and citrate of HIF-P4H-3, citrate being the most effective inhibitor of FIH with a K(i) of 110 microM. Culturing of cells with fumarate diethyl or dimethyl ester, or a high concentration of monoethyl ester, stabilized HIF-1alpha and increased production of vascular endothelial growth factor and erythropoietin. Similar, although much smaller, changes were found in cultured fibroblasts from a patient with fumarate hydratase (FH) deficiency and upon silencing FH using small interfering RNA. No such effects were seen upon culturing of cells with succinate diethyl or dimethyl ester. As FIH was not inhibited by fumarate, our data indicate that the transcriptional activity of HIF is quite high even when binding of the coactivator p300 is prevented. Our data also support recent suggestions that the increased fumarate and succinate levels present in the FH and succinate dehydrogenase-deficient tumors, respectively, can inhibit the HIF-P4Hs with consequent stabilization of HIF-alphas and effects on tumor pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss-of-function mutations in SDH and FH cause a build-up of succinate and fumarate, respectively87. Accordingly, increased levels of succinate and fumarate caused by mutations in these genes can compete with αKG and inhibit activity of HIF hydroxylases and thus induce normoxic HIF1α activity in vitro88,89.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [89]
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–516 of 516
Yu, H., Su, S., Ma, Z., Xu, Z., & Yi, H. (2026) · The FASEB Journal · doi:10.1096/fj.202503998r
Targeting the metabolic environment to modulate T cell effector function
Matias, M. I. (2019) · theses.fr (ABES) · doi:10.70675/0582ddaaze61dz4707z9cb1zdb8fe1d82653
Li, M., Rong, Y., Yu, Q., Su, Y., Xi, Y., Long, Y., Xie, Y., Sun, H., Hao, J., Yang, F., et al. (2026) · Bioresource Technology · doi:10.1016/j.biortech.2026.134888
Current research on the role of HIF in intervertebral disc degeneration
Miao, J., Cai, S., Hou, Q., Luo, R. C. N., & Ma, X. (2026) · European Spine Journal · doi:10.1007/s00586-026-10109-w
Pang, Y., Wang, Z., Liu, Y. L., Feng, C., Song, Y., Cao, S., Wang, D., Zhang, L., Lü, P., & Yu, L. (2026) · Toxicology · doi:10.1016/j.tox.2026.154532
Yao, C., Zheng, W., Jin, Y., Sheng, J., Kang, M., Zhong, J., Li, M., Duan, L., & Yuan, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1819389
Ganapathy, V., Sivaprakasam, S., Bhutia, Y. D., Prasad, P. D., & Thangaraju, M. (2026) · Cells · doi:10.3390/cells15191811
Wang, Y., & Zhao, P. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1866390
Fumarate and Its Esters: Physiology, Pathology, Molecular Mechanisms, Diseases, and Therapy
Zhu, P., You, M., Zeng, Y., Zhang, J., Chen, S., Rong, R., & Xia, X. (2026) · MedComm · doi:10.1002/mco2.71059
BindingDB (2024) · UC San Diego · doi:10.7270/q2j107cr
BindingDB (2013) · UC San Diego · doi:10.7270/q26q1zjv
Metabolic Adaptation in Reprogrammed Cancer Cells
Marks, K. M., & Kung, C. K.-H. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_7
Mitochondrion: A Novel Center for Cancer Cell Signaling
Miriyala, S., Holley, A. K., & Clair, D. K. S. (2014) · Springer eBooks · doi:10.1007/978-94-017-8984-4_1
Metadata
- Authors
- Koivunen, P., Hirsilä, M., Remes, A. M., Hassinen, I. E., Kivirikko, K. I., & Myllyharju, J.
- Affiliations
- University of Oulu (FI)
- Corresponding author
- Myllyharju, Johanna
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 282
- Issue
- 7
- Pages
- 4524-4532
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2004183689
- Semantic Scholar
- c3ddd6b07c5b433f324955c53930fb199e6ecc2a
- Cited by
- 521
- References
- 43
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 23 · 2023: 23 · 2022: 23 · 2021: 39 · 2020: 25 · 2019: 38 · 2018: 25 · 2017: 28 · 2016: 29 · 2015: 33 · 2014: 29 · 2013: 36 · 2012: 32
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
- Keywords
- hypoxia-inducible factor, FIH, citric acid cycle intermediates, fumarate, succinic acid, oxaloacetate, citrate, fumarate hydratase deficiency, succinate dehydrogenase deficiency, HIF-1α stabilization, vascular endothelial growth factor, erythropoietin, p300 coactivator, cancer metabolism
- MeSH terms
- Cell Line, Citric Acid Cycle, Dose-Response Relationship, Drug, Enzyme Inhibitors, Erythropoietin, Fibroblasts, Fumarate Hydratase, Mixed Function Oxygenases, Neoplasms, Procollagen-Proline Dioxygenase, Succinate Dehydrogenase, Transcription, Genetic, Gene Expression Regulation, Enzymologic, Vascular Endothelial Growth Factor A, p300-CBP Transcription Factors, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
